2002, ISBN: 0896038769, Lieferbar binnen 4-6 Wochen Shipping costs:Versandkostenfrei innerhalb der BRD

Internationaler Buchtitel. In englischer Sprache. Verlag: SPRINGER VERLAG GMBH, 408 Seiten, L=238mm, B=161mm, H=26mm, Gew.=871gr, [GR: 16960 - HC/Medizin/Andere Fachgebiete], [SW: - Medi… More...

Internationaler Buchtitel. In englischer Sprache. Verlag: SPRINGER VERLAG GMBH, 408 Seiten, L=238mm, B=161mm, H=26mm, Gew.=871gr, [GR: 16960 - HC/Medizin/Andere Fachgebiete], [SW: - Medical / Nursing], Gebunden, Klappentext: Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies. Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies.<

ISBN: 9780896038769

Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of thes… More...

Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies. Melanoma: Biologically Targeted Therapeutics Borden, Ernest C. Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies.<

2002, ISBN: 9780896038769

[PU: Humana], Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality fr… More...

[PU: Humana], Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein signal transduction pathways within melanoma cells or in the endothelial cells constituting the necessary angiogenic support for tumor growth. The great promise of these therapies and their cellular targets constitutes the basis for Melanoma: Biologically Targeted Therapeutics. THE CLINlCAL PROBLEM More than four million people will be diagnosed with melanoma in the first decade of the 21st..., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 388, [GW: 1g], Banküberweisung, PayPal, Klarna-Sofortüberweisung, [CT: Sonstiges / Sonstiges]<

2002, ISBN: 9780896038769

2002 ed., Hardcover, Buch, [PU: Humana Press Inc.]